Introduction
============

Globally, lung cancer is the leading cause of cancer death.[@B1] Non-small-cell lung cancer (NSCLC), which is usually diagnosed at an advanced stage, accounts for the majority of lung cancer cases. In a clinical setting, an accurate prognosis is essential to determine treatment modalities and to manage patients with advanced NSCLC. To date, the prognosis of advanced NSCLC has been reported to be closely related to tumor progression, which is usually assessed in practice based on tumor response to therapy.

Along with tumor progression, anemia is one of the most frequently observed symptoms associated with solid tumors as well as hematologic malignancies. Anemia is a condition of insufficient oxygen-carrying capacity, defined as a low level of hemoglobin in the blood. Although the prevalence of anemia in patients with cancer has been reported to range from 30% to 77%,[@B2] few studies have reported the effect of anemia on survival. Furthermore, the association of anemia with survival outcome remains controversial. In patients with NSCLC, there have been conflicting reports on the relationship between hemoglobin level and survival duration.[@B3]-[@B7]

Ferritin was originally identified as an iron-storage protein, which acts as a buffer for iron balance, and the level of ferritin is used as a diagnostic parameter for iron-deficiency anemia. As hyperferritinemia has been reported in cancer patients,[@B8] serum ferritin has been suggested as a tumor marker in the diagnosis of malignancies.[@B9] Recent studies have demonstrated that serum ferritin is a multifunctional protein, with antioxidant, ant-inflammatory, and anticarcinogenic roles, in addition to its role in iron storage.[@B10] An elevated serum ferritin level is reportedly associated with pathologic immunosuppression, proliferation, and angiogenesis, and could be an indicator of malignant disease.[@B11] In clinical studies, the serum ferritin level has been correlated with the response rate to platinum-based chemotherapy in patients with advanced NSCLC,[@B12] and an elevated serum ferritin level was an independent prognostic factor for a poor survival outcome in patients with advanced NSCLC.[@B13] Regarding the mechanism in cancer, a study reported that elevated serum ferritin is the result of inflammation and oxidative stress rather than iron overload.[@B14] High levels of ferritin and superoxide dismutase in the exhaled breath condensate of patients with NSCLC were associated with decreased survival time.[@B15]

Both hemoglobin and ferritin are iron-associated proteins in the blood. Hemoglobin carries oxygen, which is bound to the iron ion-coordinated heme component in body tissues, and ferritin is the major iron-binding protein that stores and releases iron in tissues. We previously reported the prognostic significance of serum ferritin in patients with advanced NSCLC compared with other host-related biomarkers.[@B13] Based on clinical experience, we identified that serum ferritin level was inversely correlated with hemoglobin level. As the tumor progressed in patients with advanced NSCLC, we observed that the serum ferritin level increased as the hemoglobin level decreased. Consequently, we investigated the relationship among hemoglobin, ferritin, and overall survival (OS) in advanced NSCLC. The research question from these observations was whether the ratio of ferritin-to-hemoglobin can predict the prognosis of advanced NSCLC. Therefore, this study aimed to investigate the prognostic significance of the ferritin-to-hemoglobin ratio for survival in patients with advanced NSCLC.

This is the first study to investigate the prognostic utility of the ferritin-to-hemoglobin ratio in patients with cancer. If the ferritin-to-hemoglobin ratio proves to be useful for predicting prognoses, it will facilitate the classification of patients according to their prognoses and allow for the identification of more appropriate treatment modalities. To manage patients with advanced cancer in clinical practice, a decision on appropriate treatment modalities increases the effectiveness of the treatment and allows patients to improve their quality of life. Therefore, as a first step toward identifying new prognostic factors, this study examined the prognostic significance of the ferritin-to-hemoglobin ratio for survival in patients with advanced NSCLC.

Methods
=======

This retrospective review of the medical records of patients with advanced NSCLC was approved by the Institutional Review Board of Kyung Hee University Hospital at Gangdong (KHNMC-OH-IRB 2017-12005).

Eligibility
-----------

Patients with pathologically confirmed advanced NSCLC who were older than 18 years were included. Advanced NSCLC was defined as stage IIIB and IV based on the classification by the American Joint Committee on Cancer, 7^th^ edition.[@B16] Patients with Eastern Cooperative Oncology Group-performance status (ECOG-PS) scores of 0-2 who underwent laboratory tests at the initiation of treatment were enrolled. Those with brain metastasis were also included.

Patients who did not undergo laboratory tests at the initiation of treatment and those who were concurrently undergoing any conventional cancer therapy, such as chemotherapy or radiotherapy, were excluded. In addition, patients who underwent chemotherapy or radiotherapy 3 weeks before the time of the baseline laboratory tests were also excluded to eliminate the confounding effects of conventional cancer therapy. Patients with inadequate liver or renal function as revealed by abnormal levels of aspartate transaminase, alanine aminotransferase, total bilirubin, blood urea nitrogen, and creatinine and patients supported with supplemental oxygen were also excluded. Patients who were at a high risk of oncologic emergencies, such as superior vena cava syndrome and cardiac tamponade, were not eligible for this study.

Variables
---------

ECOG-PS score, histologic type, tumor stage, the presence of metastasis, and hemoglobin, ferritin, C-reactive protein (CRP), and other biologic marker levels were investigated. The continuous variable prognostic factors were dichotomized based on cutoff values. Age was dichotomized with 65 years set as the criterion for elderly patients. The CRP cutoff level was 10 mg/L, based on the criteria for inflammation scores. The hemoglobin cutoff levels were 12 g/dL for women and 13 g/dL for men, which are the cutoff values used in anemia studies.[@B17] The serum ferritin cutoff values were 200 ng/mL in men and 150 ng/mL in women, which indicate a severe risk of iron overload according to the serum ferritin guidelines of the World Health Organization.[@B18] The optimal cutoff value of the ferritin-to-hemoglobin ratio for survival was determined using receiver operating characteristics (ROC) analysis to maximize sensitivity and specificity.

Management
----------

Patients were managed with Korean medicine (KM), including herbal medicines and acupuncture. In this study, *Rhus verniciflua* Stokes (RVS) extract was used as the main anticancer agent. RVS, known as the lacquer tree in East Asia, has been reported to have apoptotic, antiproliferative, antiangiogenic, and anti-tumor migration effects on various cancer types.[@B19]-[@B23] Despite the anticancer effect of RVS, the use of RVS has been limited owing to the presence of urushiol, a toxic allergen. After removing the urushiol, the RVS extract was obtained through a standardized method and then concentrated and lyophilized into a powdered form. The major compounds in the final RVS extract were examined and quantified to ensure the absence of urushiol and to maintain consistent quality. The RVS extract was administered orally in a 500-mg capsule formulation. Three capsules containing a total of 1500 mg of RVS extract were used as a daily dose.

In terms of clinical use, the RVS extract has prolonged OS in patients with advanced NSCLC when used concurrently with first-line chemotherapy, as maintenance therapy after first-line chemotherapy, and as a second-line treatment.[@B24], [@B25]

Overall survival
----------------

In this study, OS was defined as the period from the first day of KM management to the date of death from any cause. When patients were lost to follow-up or if death was not recorded, the patient was regarded as censored. The survival time of censored patients was defined as the period from KM management initiation to the last day of follow-up at the clinic.

Statistical Analysis
--------------------

Clinicopathologic characteristics of enrolled patients were analyzed using descriptive analysis. Survival time was estimated using Kaplan-Meier survival curves and compared with log-rank tests. Cox proportional hazards regression was used to identify the prognostic effect for survival. The prognostic effect of the ferritin-to-hemoglobin ratio was assessed after controlling for confounding factors that may influence survival and that showed a relationship with the ferritin-to-hemoglobin ratio. Multivariate modeling was performed using full models with high-priority factors to avoid bias caused by overlapping factors. Subgroup analysis according to the ferritin-to-hemoglobin ratio was performed using a chi-square test to identify the characteristics of patients. The relationship between the ferritin-to-hemoglobin ratio and other biomarkers was analyzed using correlation analysis. Statistical analyses were conducted using SAS E-guide version 4.2 software (SAS Institute, Cary, NC), and the figures of the ROC and Kaplan-Meier survival curves were modified using MedCalc statistical software version 17.7 (MedCalc Software Bvba, Ostend, Belgium).

Results
=======

The clinicopathologic characteristics and biologic markers of 138 patients who met the eligibility criteria (Figure [1](#F1){ref-type="fig"}) are summarized in Table [1](#T1){ref-type="table"}. Of the 138 enrolled patients, 79 (57.3%) were men, and 59 (42.8%) were older than 65 years. The majority of patients (126 \[91.3%\]) had stage IV disease and had more than one organ with metastasis. Fifty-eight patients (42%) had an ECOG-PS of 2. Adenocarcinoma and squamous cell carcinoma accounted for 68.1% and 21.0% of cases, respectively. Seventy-eight patients (56.5%) previously underwent at least one chemotherapy regimen, and 60 patients (43.5%) were chemotherapy-naïve. The median time to initiate KM management was 4.8 months after the initial NSCLC diagnosis and 3.5 months after a metastatic NSCLC diagnosis.

The median hemoglobin level was 11.9 (range, 6.8-14.9) g/dL, the median serum ferritin level was 180.7 (range, 6.2-3118.5) ng/mL, and the median ferritin-to-hemoglobin ratio was 14.5 (range, 0.6-294.2). The correlation analysis revealed that hemoglobin and ferritin had a weakly negative relationship (*r*=- 0.26; *P*=0.002).

The optimal cutoff value for the ferritin-to-hemoglobin ratio was 13, with a sensitivity of 58.5% and a specificity of 80% (area under the curve, 0.68; *P* = 0.004; Figure [2](#F2){ref-type="fig"}). The median OS of the enrolled patients was 11.5 months (95% confidence interval \[CI\], 10.7-14.8 months). In the comparison of the survival between dichotomized groups according to the cutoff value of the ferritin-to-hemoglobin ratio, the low ferritin-to-hemoglobin ratio group showed a significant prolongation of survival time (19.7 vs. 8.5 months; *P* \< 0.001; Figure [3](#F3){ref-type="fig"}).

To identify the prognostic factors associated with the ferritin-to-hemoglobin ratio, correlation analysis was performed with other potential prognostic factors. Among other factors, CRP, an indicator of systemic inflammation, was significantly correlated with the ferritin-to-hemoglobin ratio, showing a moderate positive relationship (*r* = 0.62,*P* \< 0.001).

Cox proportional hazards regression was performed to identify the predictive markers for survival. Among the clinicopathologic factors, age ≥65 years (hazard ratio \[HR\], 1.64; 95% CI, 1.14-2.35; *P* = 0.008), poor ECOG-PS (HR, 2.01; 95% CI, 1.40-2.88; *P* \< 0.001), and increased number of organs with metastasis (HR, 1.89; 95% CI, 1.3-2.73; *P* \< 0.001) were associated with a significantly worse survival outcome. Regarding the biomarkers, patients with an elevated CRP level (HR, 2.54; 95% CI, 1.76-3.68; *P* \< 0.001) or increased ferritin level (HR, 1.91; 95% CI, 1.33-2.73; *P* \< 0.001) showed significantly poorer survival outcomes. In contrast, an elevated hemoglobin level (HR, 0.69; 95% CI, 0.48-0.99; *P* = 0.045) showed favorable survival outcomes. An increased serum ferritin-to-hemoglobin ratio was associated with significantly worse survival (HR, 2.19; 95% CI, 1.52-3.16; *P* \< 0.001; Table [2](#T2){ref-type="table"}).

Considering the influence of confounding factors on survival, multivariate analysis was performed after controlling for age, ECOG-PS, number of organs with metastasis, and CRP. In this analysis, age ≥65 years (HR, 2.03; 95% CI, 1.38-2.98; *P* \< 0.001), increased CRP level (HR, 1.95; 95% CI, 1.30-2.93; *P* = 0.001), and an elevated ferritin-to-hemoglobin ratio (HR, 1.94; 95% CI, 1.29-2.91; *P* = 0.002) were significantly associated with a poor survival outcome as independent prognostic factors for survival (Table [2](#T2){ref-type="table"}).

A subgroup analysis according to the ferritin-to-hemoglobin ratio was performed to compare the differences in other factors. The high ferritin-to-hemoglobin ratio group had a significantly larger proportion of male patients (*P* = 0.036), and a high ferritin-to-hemoglobin ratio was associated with poor ECOG-PS (*P* \< 0.001), an increased number of organs with metastasis (*P* = 0.001), and an elevated CRP level (*P* \< 0.001) (Table [3](#T3){ref-type="table"}).

Discussion
==========

The results of this study led to several interesting observations. In terms of the anatomical extent of tumor, the distinction between OS time of stage IIIB and IV advanced NSCLC was not significant, whereas the number of organs with metastasis had a significant effect on survival. However, as the number of stage IIIB cases in the present study were relatively low compared to the number of stage IV cases, we are unable to conclusively state that tumor-node-metastasis staging did not affect OS. Our results are consistent with the recent classification of distant metastasis into a single extrathoracic metastasis and multiple extrathoracic metastases by the classification of stage IV lung cancer.[@B26]

Histologic tumor type has been reported as a significant prognostic factor for survival in patients before initiating first-line therapy after diagnosis of advanced NSCLC. Squamous cell carcinoma has been associated with an unfavorable survival outcome.[@B27] In this study, the histologic distinction of squamous and non-squamous NSCLC did not reveal a difference in survival outcome. This result may be due to the characteristics of the enrolled patients; 29% had previously undergone multiple lines of systemic therapy, which implies the presence of refractory cancer. Therefore, histological subtype may not affect the outcome of KM treatment, unlike that of systemic chemotherapy.

Hemoglobin, which transports oxygen bound to iron ions, is an important biomarker for anemia. Anemia has reportedly been diagnosed in more than 70% of patients with solid tumors as well as in patients with hematologic malignancies, indicating that it is affected by disease course or therapeutic procedures.[@B2] Cancer-related anemia is a multifactorial issue related to nutritional, metabolic, and immune components of cancer and is associated with the progress and severity of cancer.[@B28] Hemoglobin has not been directly implicated in tumor progression; therefore, the prognostic effect of hemoglobin for survival has been contradicted by several observational studies.[@B3]-[@B7]

In contrast, ferritin, an iron storage protein, has been found to be associated with cancer progression in a number of pathways since its association with cancer was first published in 1977.[@B8] Ferritin has been demonstrated to play a role in tumor progression through its relationship with macrophages, regulatory effect on angiogenesis, association with inflammation as an acute-phase protein, and relevance in oxidative stress.[@B29]

Ferritin is a 24-subunit protein composed of two types of subunits: ferritin heavy chain and ferritin light chain. The source of serum ferritin is still unclear; however, some studies reported that serum ferritin is secreted by hepatocytes and macrophages. [@B30] In particular, macrophages were revealed as a major cellular source of serum ferritin.[@B30], [@B31] Tumor-associated macrophages (TAMs) play a major role in tumor progression through direct mechanisms to secret procarcinogenic molecules and indirect mechanisms of iron binding and ferritin release.[@B32] TAM ferritin in the tumor microenvironment was shown to be an important element in promoting cancer cell proliferation and tumor growth in breast cancer.[@B31], [@B33] These findings that macrophages are an important cellular source of ferritin and that TAM is associated with ferritin may explain the significantly elevated level of serum ferritin in inflammatory conditions and the close relationship to the CRP level. This phenomenon is also consistent with the results of the correlation analysis of the present study, which showed that the ferritin-to-hemoglobin ratio was significantly correlated to the CRP level with a moderate positive relationship. Therefore, further studies may reveal a functional link of serum ferritin that connects carcinogenesis and inflammation.

In terms of the regulatory effect on angiogenesis, ferritin promotes tumor angiogenesis by binding high molecular weight kininogen, thereby enhancing migration and tube formation.[@B29], [@B34] Regarding oxidative stress, ferritin is considered a surrogate marker for oxidative stress, and a high level of serum ferritin could accelerate the generation of reactive oxygen species or oxidative DNA damage in cells.[@B35] Studies also found that ferritin was associated with tumor suppressor p53 protein and that downregulation of ferritin increased the sensitivity of breast cancer cells to chemotherapy.[@B29] Moreover, increasing evidence of the relevance of ferritin to cancer through various mechanisms has been reported, such as the association with nuclear factor-кB signaling [@B36] and mitochondrial ferritin in tumor cells,[@B37]-[@B40] among others.

In a clinical study, the ferritin level of breast cancer tissue was six-fold higher than that in normal or benign breast tissue,[@B41] indicating that the level of ferritin can be used as an indicator or a prognostic biomarker of breast cancer.[@B33], [@B42], [@B43] In addition to breast cancer, the serum ferritin level has also been found to be elevated in patients with lung cancer, pancreatic cancer, hepatocellular carcinoma, colorectal cancer, leukemia, and lymphoma, and the level was closely associated with the prognosis.[@B13], [@B33], [@B43]-[@B51] We have also reported the prognostic effect of serum ferritin as a host-related biomarker for survival in patients with colon cancer and NSCLC.[@B13], [@B50] The reason we pay attention to the ferritin-to-hemoglobin ratio is that, as the cancer progresses, we frequently observe that the ferritin concentration increases while the hemoglobin level decreases. This phenomenon differs from iron-deficiency anemia in which ferritin and hemoglobin decrease simultaneously. Similarly, a large observational study reported that hemoglobin levels were inversely associated with ferritin levels in patients with lung cancer, which is different from that observed in patients with gastrointestinal cancers.[@B28] Based on these findings, we aimed to investigate the prognostic significance of the ferritin-to-hemoglobin ratio for survival in patients with advanced NSCLC.

Our results showed that the ferritin-to-hemoglobin ratio was an independent prognostic factor for predicting survival in patients with advanced NSCLC. As a prognostic factor, the ferritin-to-hemoglobin ratio was comparable to that of the level of CRP, a well-known biomarker of systemic inflammation. As mentioned in previous studies, the main source of ferritin is macrophages, which means that ferritin is secreted by the host and not by the tumor. Thus, ferritin is a unique host-related biomarker that represents tumor burden. Therefore, both ferritin and hemoglobin are host-related factors that reflect the overall patient condition, implying multiple physiological and pathological processes. Hemoglobin is a biomarker routinely included in follow-up blood counts, and ferritin is a biomarker that provides information with respect to anemia and tumor progression.

The ferritin-to-hemoglobin ratio is calculated by dividing the ferritin level, which increases with tumor progression, by the hemoglobin level, which reflects the overall condition of the host. The ratio changes depending on the relationship between the tumor and the host. The ferritin-to-hemoglobin ratio maximizes the prognostic impact of ferritin and hemoglobin, and an increased ratio implies tumor progression, based on the results of this study. To validate the clinical interpretation of the ferritin-to-hemoglobin ratio, more studies on the pathophysiological roles related to the tumor and host are necessary.

In clinical practice, the individual levels of hemoglobin and ferritin may be used to predict survival by means of the ferritin-to-hemoglobin ratio, which can provide useful information for managing patients with advanced cancer. Additionally, there is an economic advantage to low-cost tests; therefore, the ferritin-to-hemoglobin ratio may be used in various clinical settings.

Considering that a high ferritin-to-hemoglobin ratio was associated with a poor ECOG-PS, multiple organ metastases, and increased CRP levels, and that the main source of ferritin is the macrophage involved in tumor progression, the ratio can be more useful to predict prognosis in patients with relapsed or refractory advanced cancer than in those with newly diagnosed early cancer. In clinical practice, the ferritin-to-hemoglobin ratio could be applied as a prognostic index to select appropriate treatment modalities for anticancer therapy such as palliative care or supportive care. The need for detailed distinctions in advanced cancer coincides with the recently revised classification of stage IVA and IVB according to single or multiple extrathoracic metastases, which was also intended to facilitate accurate prediction of prognosis and survival in lung cancer.[@B26], [@B52]

As a retrospective cohort study, this study has limitations in that a comparison of various variables, including hepcidin, transferrin, and iron, that may have potential associations with ferritin and hemoglobin were not measured.[@B32] The study population was also limited to patients who underwent KM treatment at a single institution. Therefore, to extrapolate our results to the clinical setting, prospective studies with various candidate variables are necessary. In addition, to provide a basis for the results observed in this clinical study, research on the pathophysiologic roles of ferritin and hemoglobin in cancer progression will be necessary for the understanding of their mechanism of action. Despite these limitations, considering that an observational study using existing resources is a powerful method to generate evidence to test new hypotheses, this is the first study to investigate the ferritin-to-hemoglobin ratio, and the results contribute to the prediction of prognosis in patients with cancer.
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###### 

Characteristics of the enrolled patients

  Variables                          N (%)
  ---------------------------------- --------------------
  **Clinicopathologic factors**      
  Age (years)                        
  \<65                               82 (59.4)
  ≥65                                56 (40.6)
  Sex                                
  Men                                79 (57.3)
  Women                              59 (42.8)
  ECOG-PS                            
  0                                  8 (5.8)
  1                                  72 (52.2)
  2                                  58 (42.0)
  Histologic type                    
  Squamous cell carcinoma            29 (21.0)
  Adenocarcinoma                     94 (68.1)
  other                              15 (10.9)
  Stage                              
  IIIB                               12 (8.7)
  IV                                 126 (91.3)
  Number of organs with metastasis   
  0                                  12 (8.7)
  1                                  55 (39.9)
  ≥2                                 71 (51.4)
  Prior surgery                      
  No                                 104 (75.4)
  Yes                                34 (24.6)
  Prior chemotherapy                 
  None                               60 (43.5)
  1st line                           38 (27.5)
  2nd line                           40 (29)
  Prior radiotherapy                 
  No                                 87 (63.0)
  Yes                                51 (37.0)
  **Biologic markers**               
  CRP (mg/L)                         4.1 (0.1-252.8)\*
  ≤10                                81 (58.7)
  \>10                               57 (41.3)
  Hemoglobin (g/dL)                  11.9 (6.8-14.9)
  Men \<13, women \<12               80 (58.0)
  Men ≥13, women ≥12                 58 (42.0)
  Ferritin (ng/mL)                   180.7 (6.2-3118.5)
  Men ≤200, women ≤150               69 (50)
  Men \>200, women \>150             69 (50)
  Ferritin/hemoglobin                14.5 (0.6-294.2)
  \<13                               63 (45.7)
  ≥13                                75 (54.3)

\*Median (range). Abbreviations: CRP, C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group-performance status.

###### 

Prognostic effects of host-related biomarkers according to Cox proportional hazards regression analysis

  Variable                        Univariate analysis   Multivariate analysis                                
  ------------------------------- --------------------- ----------------------- --------- ------ ----------- ---------
  **Clinicopathologic factors**                                                                              
  Age (years)                                                                                                
  \<65                            1                                                       1                  
  ≥65                             1.64                  1.14-2.35               0.008     2.03   1.38-2.98   \<0.001
  Sex                                                                                                        
  Men                             1                                                                          
  Women                           0.73                  0.51-1.04               0.084                        
  ECOG-PS                                                                                                    
  0-1                             1                                                       1                  
  2                               2.01                  1.40-2.88               \<0.001   1.37   0.93-2.02   0.109
  Histologic type                                                                                            
  Squamous cell carcinoma         1                                                                          
  Non-squamous cell carcinoma     0.69                  0.45-1.08               0.103                        
  Stage                                                                                                      
  IIIB                            1                                                                          
  IV                              1.12                  0.58-2.13               0.74                         
  No. of organs with metastasis                                                                              
  0-1                             1                                                       1                  
  ≥2                              1.89                  1.31-2.73               \<0.001   1.35   0.91-2.01   0.133
  **Biomarkers**                                                                                             
  CRP (mg/L)                                                                                                 
  ≤10                             1                                                       1                  
  \>10                            2.54                  1.76-3.68               \<0.001   1.95   1.30-2.93   0.001
  Hemoglobin (g/dL)                                                                                          
  Men \<13, women \<12            1                                                                          
  Men ≥13, women ≥12              0.69                  0.48-0.99               0.045                        
  Ferritin (ng/mL)                                                                                           
  Men ≤200, women ≤150            1                                                                          
  Men \>200, women \>150          1.91                  1.33-2.73               \<0.001                      
  Ferritin/hemoglobin                                                                                        
  \<13                            1                                                       1                  
  ≥13                             2.19                  1.52-3.16               \<0.001   1.94   1.29-2.91   0.002

Abbreviations: CI, confidence interval; CRP; C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group-performance status; HR, hazard ratio.

###### 

Clinical characteristics according to the ferritin-to-hemoglobin ratio

  -------------------------------------------------------------------------------------------------
  Variables                       Ferritin/\                 Ferritin/\                *P-* value
                                  hemoglobin \<13 (n = 63)   hemoglobin ≥13 (n = 75)   
  ------------------------------- -------------------------- ------------------------- ------------
  Age (years)                                                                          0.232

  \<65                            34                         48                        

  ≥65                             29                         27                        

  Sex                                                                                  0.036

  Men                             30                         49                        

  Women                           33                         26                        

  ECOG-PS                                                                              \<0.001

  0-1                             48                         32                        

  2                               15                         43                        

  Histologic type                                                                      0.92

  Squamous cell carcinoma         13                         16                        

  Non-squamous cell carcinoma     50                         59                        

  Stage                                                                                0.126

  IIIB                            8                          4                         

  IV                              55                         71                        

  No. of organs with metastasis                              0.001                     

  0-1                             40                         27                        

  ≥2                              23                         48                        

  CRP (mg/L)                                                                           \<0.001

  ≤10                             50                         31                        

  \>10                            13                         44                        
  -------------------------------------------------------------------------------------------------

Abbreviations: CRP; C-reactive protein; ECOG-PS, Eastern Cooperative Oncology Group-performance status.
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